Industry News
Volasertib* receives FDA Breakthrough Therapy Designation for treatment of patients with acute myeloid leukaemia
Sep 19, 2013
Boehringer Ingelheim Pharmaceuticals, Inc. have announced the FDA has granted Breakthrough Therapy designation to volasertib*, an investigational inhibitor of polo-like kinase (Plk), being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy... Read More
Fragile X syndrome protein linked to breast cancer progression
Sep 19, 2013
Claudia Bagni*, has identified the way Fragile X Mental Retardation Protein or FMRP contributes to the progression of breast cancer. For this research the group of Bagni collaborated with colleagues from the VIB/KU Leuven departments of Bart De Strooper and Peter Carmeliet**, with Patrick Neven*** and with several research centers and Hospitals in Italy and the UK... Read More
Possible antidote discovered for tamoxifen-related mental fog
Sep 19, 2013
A team from the University of Rochester Medical Center has shown scientifically what many women report anecdotally: that the breast cancer drug tamoxifen is toxic to cells of the brain and central nervous system, producing mental fogginess similar to "chemo brain... Read More
Workers involved in Gulf oil spill cleanup show hematological and hepatic abnormalities
Sep 19, 2013
A new study reports that workers exposed to crude oil and dispersants used during the Gulf oil spill cleanup display significantly altered blood profiles, liver enzymes, and somatic symptoms compared to an unexposed control group. Investigators found that platelet counts were significantly decreased in the exposed group, while both hemoglobin and hematocrit levels were notably increased... Read More
Discovery of potent tumor-suppressor in lung cancer
Sep 19, 2013
New research shows that microRNA-486 is a potent tumor-suppressor molecule in lung cancer, and that the it helps regulate the proliferation and migration of lung-cancer cells, and the induction of programmed cell death, or apoptosis, in those cells. The preclinical study was led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G... Read More
Scientists improve popular chemotherapy drug
Sep 19, 2013
Scientists have discovered a way to make significant improvements to a popular cancer cell-killing drug called vinblastine, according to a study published in the journal ACS Medicinal Chemistry Letters... Read More
Extremely potent and improved new derivatives of successful anticancer drug
Sep 19, 2013
Scientists at The Scripps Research Institute (TSRI) have found a way to make dramatic improvements to the cancer cell-killing power of vinblastine, one of the most successful chemotherapy drugs of the past few decades. The team's modified versions of vinblastine showed 10 to 200 times greater potency than the clinical drug... Read More
Cancer growth in mice slowed by depletion of 'traitor' immune cells
Sep 19, 2013
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself... Read More
Out of control mucus-regulating protein receptors in uterine and pancreatic cancers
Sep 19, 2013
A "vicious cycle" produces mucus that protects uterine and pancreatic cancer cells and promotes their proliferation, according to researchers at Rice University. The researchers offer hope for a therapeutic solution. They found that protein receptors on the surface of cancer cells go into overdrive to stimulate the production of MUC1, a glycoprotein that forms mucin, aka mucus... Read More
Immune marker predicts transplant success and improves selection of bone marrow donors
Sep 19, 2013
The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children's Research Hospital. The findings appear in the Journal of Clinical Oncology. The research builds on an earlier St... Read More
Previous Page Next Page